Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Immunome Inc's Business Segments
Immunome Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2025
Reportable Segments
1
Largest Segment
Single reportable segment
Total Revenue
$ 3
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2025
- Single reportable segment100%
Revenue by Reportable Segment - Q1 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single reportable segment | $ 3 | 100% |
Description of Immunome Inc
Immunome Inc. is a biotechnology company that focuses on developing novel immunotherapies for the treatment of infectious diseases and cancer. The company utilizes advanced technologies, including high-throughput sequencing, to analyze the human immune system and identify naturally occurring antibodies with therapeutic potential.
Immunome's primary goal is to harness the power of the immune system to develop targeted therapies that can effectively combat a wide range of diseases. They recognize the incredible diversity and specificity of the immune response and believe that by understanding and leveraging these characteristics, they can develop highly effective treatments.
One of the key strengths of Immunome is their proprietary discovery platform. This platform uses advanced computational algorithms and bioinformatics tools to analyze immune repertoires at an unprecedented scale. By studying the diversity of antibodies present in patients with a particular disease, the company can identify rare and potent antibodies that could be used to develop new therapies.
Immunome's technology also allows them to identify conserved antibody targets across different strains of a pathogen. This is particularly important in the field of infectious diseases, as it enables the development of broad-spectrum therapies that can effectively target multiple strains of a pathogen, reducing the chances of resistance developing.
In addition to infectious diseases, Immunome is also actively involved in the development of immunotherapies for cancer. They believe that the immune system can play a crucial role in the fight against cancer by specifically targeting tumor cells while sparing healthy tissues. The company's platform allows them to identify tumor-specific antibodies that can be used to develop personalized cancer therapies.
Immunome has a strong track record of collaboration with leading academic institutions and has established partnerships with various pharmaceutical companies. These collaborations provide access to expertise, resources, and clinical samples, allowing them to accelerate the development of their therapeutic candidates.
Overall, Immunome Inc. is a biotechnology company that is at the forefront of leveraging the immune system to develop novel therapies for infectious diseases and cancer. Through their advanced discovery platform and collaborations, they aim to bring innovative and targeted treatments to patients in need.
Immunome's primary goal is to harness the power of the immune system to develop targeted therapies that can effectively combat a wide range of diseases. They recognize the incredible diversity and specificity of the immune response and believe that by understanding and leveraging these characteristics, they can develop highly effective treatments.
One of the key strengths of Immunome is their proprietary discovery platform. This platform uses advanced computational algorithms and bioinformatics tools to analyze immune repertoires at an unprecedented scale. By studying the diversity of antibodies present in patients with a particular disease, the company can identify rare and potent antibodies that could be used to develop new therapies.
Immunome's technology also allows them to identify conserved antibody targets across different strains of a pathogen. This is particularly important in the field of infectious diseases, as it enables the development of broad-spectrum therapies that can effectively target multiple strains of a pathogen, reducing the chances of resistance developing.
In addition to infectious diseases, Immunome is also actively involved in the development of immunotherapies for cancer. They believe that the immune system can play a crucial role in the fight against cancer by specifically targeting tumor cells while sparing healthy tissues. The company's platform allows them to identify tumor-specific antibodies that can be used to develop personalized cancer therapies.
Immunome has a strong track record of collaboration with leading academic institutions and has established partnerships with various pharmaceutical companies. These collaborations provide access to expertise, resources, and clinical samples, allowing them to accelerate the development of their therapeutic candidates.
Overall, Immunome Inc. is a biotechnology company that is at the forefront of leveraging the immune system to develop novel therapies for infectious diseases and cancer. Through their advanced discovery platform and collaborations, they aim to bring innovative and targeted treatments to patients in need.
Immunome Inc. is a biotechnology company that focuses on developing therapies using its proprietary platform to target cancer and other diseases. The company’s offerings can be segmented into several key categories:
1. Therapeutic Products
a. Monoclonal Antibodies
Immunome develops monoclonal antibodies targeting specific antigens found on cancer cells. These antibodies are designed to bind to cancer cells, leading to immune-mediated destruction of these cells.
b. Therapeutic Antibodies for Infectious Diseases
The company is also involved in the development of monoclonal antibodies targeting infectious diseases. These products aim to provide passive immunity or serve as part of combination therapies for effective treatment.
c. Combination Therapies
Immunome is exploring the use of its monoclonal antibodies in combination with existing therapies (such as chemotherapy or immunotherapy) to enhance their efficacy and improve patient outcomes.
Platform Technology
Immunome utilizes a proprietary hyperimmune platform that isolates and amplifies the body’s immune response to a vast array of antigen targets, particularly those found in tumors. This platform allows for:
a. Rapid Discovery of Antibodies
The technology enables swift identification and development of therapeutic antibodies from patient-derived immune responses.
b. Broad Spectrum Antigen Targeting
Immunomes platform can target multiple antigens simultaneously, potentially leading to more effective treatments across various cancer types and other diseases.
c. Customization for Individual Patients
The adaptability of the platform allows for the development of individualized therapies tailored to the unique immune profiles of patients.
Research Services
Immunome also offers research and development services aimed at collaborating with other companies and institutions. These services include:
a. Antibody Discovery
Assistance in identifying candidate antibodies for various applications, including diagnostics and therapeutics.
b. Assay Development
Creation and optimization of assays for analyzing the efficacy and mechanisms of action of therapeutic antibodies.
c. Preclinical Studies
Conducting preclinical evaluations to assess the safety and efficacy of therapeutic candidates before they enter clinical trials.
Partnerships and Collaborations
Immunome actively engages in partnerships with other biotech and pharmaceutical companies. These collaborations can lead to co-development agreements, joint ventures, and exploration of combined therapeutic approaches. Partnerships can involve sharing technology, joint research endeavors, and co-commercialization of products.
Pipeline Products
Immunomes pipeline includes various candidates in different stages of research and development, notably targeting various cancers and other diseases. These candidates go through rigorous phases of testing, including preclinical studies, Phase I, II, and III clinical trials.
Investor Relations and Financial Services
To attract funding, Immunome engages in activities focused on investor relations, providing financial transparency and potential returns on investments. They may host events, release updates, and maintain communication to keep investors informed about product development progress and regulatory milestones.
Conclusion
In summary, Immunome Inc. is at the forefront of developing innovative immunotherapies aimed at treating cancer and infectious diseases through a combination of proprietary technology, research services, and collaborative efforts. Its pipeline reflects a commitment to advancing therapeutic options that leverage the body’s immune system, providing significant potential benefits to patients.
1. Therapeutic Products
a. Monoclonal Antibodies
Immunome develops monoclonal antibodies targeting specific antigens found on cancer cells. These antibodies are designed to bind to cancer cells, leading to immune-mediated destruction of these cells.
b. Therapeutic Antibodies for Infectious Diseases
The company is also involved in the development of monoclonal antibodies targeting infectious diseases. These products aim to provide passive immunity or serve as part of combination therapies for effective treatment.
c. Combination Therapies
Immunome is exploring the use of its monoclonal antibodies in combination with existing therapies (such as chemotherapy or immunotherapy) to enhance their efficacy and improve patient outcomes.
Platform Technology
Immunome utilizes a proprietary hyperimmune platform that isolates and amplifies the body’s immune response to a vast array of antigen targets, particularly those found in tumors. This platform allows for:
a. Rapid Discovery of Antibodies
The technology enables swift identification and development of therapeutic antibodies from patient-derived immune responses.
b. Broad Spectrum Antigen Targeting
Immunomes platform can target multiple antigens simultaneously, potentially leading to more effective treatments across various cancer types and other diseases.
c. Customization for Individual Patients
The adaptability of the platform allows for the development of individualized therapies tailored to the unique immune profiles of patients.
Research Services
Immunome also offers research and development services aimed at collaborating with other companies and institutions. These services include:
a. Antibody Discovery
Assistance in identifying candidate antibodies for various applications, including diagnostics and therapeutics.
b. Assay Development
Creation and optimization of assays for analyzing the efficacy and mechanisms of action of therapeutic antibodies.
c. Preclinical Studies
Conducting preclinical evaluations to assess the safety and efficacy of therapeutic candidates before they enter clinical trials.
Partnerships and Collaborations
Immunome actively engages in partnerships with other biotech and pharmaceutical companies. These collaborations can lead to co-development agreements, joint ventures, and exploration of combined therapeutic approaches. Partnerships can involve sharing technology, joint research endeavors, and co-commercialization of products.
Pipeline Products
Immunomes pipeline includes various candidates in different stages of research and development, notably targeting various cancers and other diseases. These candidates go through rigorous phases of testing, including preclinical studies, Phase I, II, and III clinical trials.
Investor Relations and Financial Services
To attract funding, Immunome engages in activities focused on investor relations, providing financial transparency and potential returns on investments. They may host events, release updates, and maintain communication to keep investors informed about product development progress and regulatory milestones.
Conclusion
In summary, Immunome Inc. is at the forefront of developing innovative immunotherapies aimed at treating cancer and infectious diseases through a combination of proprietary technology, research services, and collaborative efforts. Its pipeline reflects a commitment to advancing therapeutic options that leverage the body’s immune system, providing significant potential benefits to patients.